[A Retrospective Analysis of Erlotinib and TP/GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer.].
About 80% lung cancers belong to non-small cell lung cancer (NSCLC) and more than 70% are in advanced stage. The aim of this study was to evaluate the clinical efficacy and toxicity of erlotinib and GP/TP regimen on advanced non-small cell lung cancer. Ninety-one advanced NSCLC patients with different treatments from January 2007 to April 2009 in our hospital were retrospectively analyzed. Ninety-one patients were divided into the erlotinib and TP/GP group. Erlotinib group: received erlotinib 150 mg/dl TP/GP group: the original chemotherapy for advanced non-small cell lung cancer. The cycles were repeated for 21 days. The patients were given docetaxel (80 mg/m(2), d1) or gemcitabine (1 000 mg/m(2), d1, 8) +cisplatin (70 mg/m(2), d2); then the adverse reaction and clinical efficacy were recorded during 3 months. Total 91 patients were evaluated for efficacy. The total rate of effect was 23.33% in erlotinib group. The side effects were erythra, diarrhea and vomiting. Pulmonary fibrosis was found in one patient after 21 days. TP/GP group: the total rate of effect was 27.78% and 28% and the side effects were bone marrow depression and reaction of gastrointestinal tract. There were no significantly difference between the two groups in the total rate of effect (P>0.05). But the side effects were less in erlotinib group, and there were significantly difference between the two groups. Erlotinib on advanced non-small cell lung cancer shows more effectiveness and adverse reactions are tolerable. The further clinical study should be warranted.